Community update: Scholar Rock
Scholar Rock, resubmitted the Marketing Authorisation Application for apitegromab to the EMA. The company anticipates a CHMP opinion in the first half of 2027.
SMA Newsroom
Scholar Rock, resubmitted the Marketing Authorisation Application for apitegromab to the EMA. The company anticipates a CHMP opinion in the first half of 2027.